Found 5 Presentations For Request "HARRINGTON"
Presentation Topic
Filtered By
827P - An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results
- Kevin J. Harrington (London, United Kingdom)
Abstract
Background
RP2 is an enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being evaluated in an open-label, multicenter, phase 1 clinical trial as monotherapy and combined with nivolumab (nivo). Here, we present updated safety, efficacy, and biomarker data of RP2
Methods
After determination of the RP2D (106 PFU/mL intratumorally (IT) once followed by up to 7 additional doses of 107 PFU/mL via IT), a cohort of 30 patients (pts) was enrolled and treated with RP2 combined with nivo (240 mg Q2W for 4 months from the second RP2 dose, then 480 mg Q4W for 20 months). Responses were assessed using modified RECIST v1.1.
Results
Objective responses with RP2 monotherapy were observed in 3 out of 9 pts including 1 CR for ≥15 months in mucoepidermoid carcinoma, 1 PR for ≥18 months in esophageal cancer with liver metastases, 1 PR in uveal melanoma with liver metastases that progressed at 15 months. Objective responses with RP2 + nivo treatment were 44.4% in cutaneous melanoma (4/9), 25% in uveal melanoma (2/8), and 33% in SCCHN (1/3) pts. All seven responding patients had previously failed anti-PD-1 therapy, with all but one response durable to date for >425 days. The most common adverse events (grade 1-2) were pyrexia, chills, influenza-like illness, fatigue, and pruritus. No grade 4-5 events were observed. Immunohistochemistry (IHC) analysis indicated robust increases in CD8 T cell influx, PD-L1 expression, and an increase in the CD8/foxp3+ cell ratio. Clinical responses were independent of baseline CD8 T cell infiltration, PD-L1 expression levels, and prior anti-PD-1 therapy status.
Conclusions
RP2 ± nivo demonstrated good tolerability and durable systemic responses in pts with difficult-to-treat, heavily pretreated and anti-PD-1 failed advanced cancers. These data continue to support the hypothesis that oncolytic delivery of anti-CTLA-4 into tumors, with accompanying antigen release, presentation and immune activation, can provide potent systemic anti-tumor effects.
Clinical trial identification
NCT04336241.
Legal entity responsible for the study
Replimune Inc.
Funding
Replimune Inc.
Disclosure
K.J. Harrington: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Merck, MSD, Pfizer, Replimune, Oncolys, Vyriad, Idera; Financial Interests, Institutional, Other, Honoraria for lectures: Amgen, AstraZeneca, BMS, Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board, Advisory board for CD47 assets: Arch Oncology; Financial Interests, Institutional, Advisory Board, Development of DDR assets: ARTIOS; Financial Interests, Institutional, Advisory Board, Development of exosomal STING agonist: Codiak; Financial Interests, Institutional, Advisory Board, Development of oncolytic adenovirus: PsiVac; Financial Interests, Institutional, Funding, Research: AstraZeneca, Boehringer Ingelheim, MSD; Financial Interests, Institutional, Funding, Development of oncolytic HSV platform: Replimune; Non-Financial Interests, Leadership Role, Chair of Steering Committee: ART NET; Non-Financial Interests, Other, Member of Global Steering Committee: MR - Linac. J.J. Sacco: Financial Interests, Institutional, Principal Investigator: Replimune Inc ; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca, BMS, Immunocore; Financial Interests, Personal, Invited Speaker: Pierre- Fabre, BMS. P. Bommareddy: Financial Interests, Personal, Stocks/Shares: Replimune Inc . C. Ahlers: Financial Interests, Personal, Stocks/Shares: Replimune Inc . J. Wolff: Financial Interests, Personal, Stocks/Shares: Replimune Inc . M.R. Middleton: Financial Interests, Personal, Advisory Board, Advice on drug development and clinical trial design: Alkermes, Kineta, Silicon Therapeutics, Immunocore, Replimune; Financial Interests, Personal, Advisory Board, Advice on patient experience measures and research design: BMS; Financial Interests, Institutional, Invited Speaker, Fees for clinical trial conduct: Replimune; Financial Interests, Institutional, Invited Speaker, Fees for trial conduct: BMS, Alkermes, GSK, Merck KGa, MSD, Pfizer, Regeneron, Bioline, Novartis, Roche, Medivir; Financial Interests, Institutional, Funding, Educational grant towards IIS; fees for clinical trial conduct: Immunocore; Financial Interests, Institutional, Invited Speaker, Grant towards IIS: GRAIL; Non-Financial Interests, Other, Multiple roles as reviewer and committee member: Cancer Research UK; Non-Financial Interests, Member: AACR, ASCO, ACP. All other authors have declared no conflicts of interest.
1678P - The interaction between cancer cells and cancer-associated fibroblasts promotes RAS signalling in squamous cell carcinoma, resulting in an immune-suppressive tumour microenvironment and poorer survival outcomes
- Antonio J. Rullan (Sutton, United Kingdom)
Abstract
Background
Cancer-Associated Fibroblasts (CAFs) are a main component of the tumour microenvironment. Recent evidence suggests that high levels of CAFs correlate with poorer prognosis and a pro-tumorigenic microenvironment. The clinical relevance of CAF presence and the mechanisms by which they influence prognosis warrant further research.
Methods
We used publicly available RNAseq data from The Cancer Genome Atlas (TCGA), gene expression data from cancer-cell (CC)-CAF co-cultures of three different cell lines. Further in vitro validation experiments were performed on human Head and Neck cancer cell lines, patient derived CAFs and macrophages from healthy donors.
Results
We generated a gene signature that predicts the abundance of CAF/CC interaction in clinical RNAseq data from a meta-analysis of transcriptomic data derived from Cancer Cell (CC) and CAF co-cultures. This gene signature is predictive of worse overall survival in datasets of Squamous Cell Carcinoma (SCC) patients. CAF abundance and the co-culture signature are strongly correlated with RAS signalling. Mechanistically, we showed that AP-1 transcription factor genes are strongly up-regulated when CCs and CAFs are in close contact. Direct contact between CCs and CAFs upregulates the RAS pathway in both cell types through membrane bound growth factors and growth factor receptors, activating AP-1 activity. We also demonstrated that the RAS / AP-1 axis is used by CCs to induce secretion of pro-tumorigenic and immune-inhibitory cytokines from CAFs, enhancing migration of potentially immune-suppressive macrophages. Of note, patients with high expression of CC-CAF coculture genes show an immune-suppressive microenvironment. Importantly, treatment with ERK inhibitors is able to disrupt the activation of this pathway, blocking cytokine production and impairing macrophage migration.
Conclusions
In conclusion, we generated a gene signature predictive of overall survival in SCC patients, linked to cancer cell -CAF interaction and RAS signalling. This study reveals a novel mechanism of crosstalk between CCs and CAFs able to modulate the tumour immune microenvironment.
Legal entity responsible for the study
The authors.
Funding
The Francis Crick Institute, Cancer Research UK, Wellcome Trust, UK Medical Research Council, NIHR Biomedical Research Centre at The Royal Marsden and the ICR.
Disclosure
G. Giangreco: Financial Interests, Institutional, Funding: MSD. K.J. Harrington: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Merck, MSD, Pfizer, Replimune, Oncolys, Vyriad, Idera; Financial Interests, Institutional, Other, Honoraria for lectures: Amgen, AstraZeneca, BMS, Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board, Advisory board for CD47 assets: Arch Oncology; Financial Interests, Institutional, Advisory Board, Development of DDR assets: ARTIOS; Financial Interests, Institutional, Advisory Board, Development of exosomal STING agonist: Codiak; Financial Interests, Institutional, Advisory Board, Development of oncolytic adenovirus: PsiVac; Financial Interests, Institutional, Funding, Research: AstraZeneca, Boehringer Ingelheim, MSD; Financial Interests, Institutional, Funding, Development of oncolytic HSV platform: Replimune; Non-Financial Interests, Leadership Role, Chair of Steering Committee: ART NET; Non-Financial Interests, Other, Member of Global Steering Committee: MR - Linac. E. Sahai: Financial Interests, Personal, Advisory Board: Phenomic; Financial Interests, Personal and Institutional, Funding: MSD, GSK, AstraZeneca. All other authors have declared no conflicts of interest.
703TiP - A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
- Antonio Rullan (London, United Kingdom)
Abstract
Background
This study will assess whether setanaxib, an investigational nicotinamide adenine dinucleotide phosphate oxidase (NOX) 1/4 inhibitor (Calliditas Therapeutics Suisse SA), could increase cancer-associated fibroblast (CAF)-rich tumour response to pembrolizumab in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN). Pembrolizumab, a programmed cell death-1 inhibitor, is indicated as first-line treatment (tx) for rmSCCHN in some pts; however, tumour response rates are low.1,2 CAF-rich tumours suppress response to immunotherapy by excluding cluster of differentiation (CD)8+ tumour-infiltrating lymphocytes (TILs).3NOX1/4 are key drivers of fibrogenesis. Pre-clinical models suggest that, as NOX4 inhibition by setanaxib may prevent and reverse differentiation of CAFs, combination tx of setanaxib with pembrolizumab may improve clinical outcomes in CAF-rich tumours.3
Trial design
In this double-blind, placebo-controlled phase 2 trial (NCT05323656), 60 pts with rmSCCHN (Table) will be randomised 1:1 (stratified by tumour human papillomavirus status) to oral setanaxib 800 mg twice daily or placebo, plus intravenous pembrolizumab 200 mg every 3 weeks, for ≤24 months. The primary objective will be to evaluate and compare best percentage change from baseline in tumour diameter (using Response Evaluation Criteria in Solid Tumours [RECIST] 1.1) between tx arms. Key secondary objectives will include comparisons of progression-free survival per RECIST 1.1 and change from baseline in tumour CAF and CD8+ TIL levels between tx arms. The study is currently recruiting in France, Germany, Poland, Spain, the UK and the USA. 1NICE https://www.nice.org.uk/guidance/ta661/ accessed 13/04/22; 2Bauml J
CAF: cancer-associated fibroblast; HPV: human papillomavirus; PD-L: programmed death-ligand; RECIST: Response Evaluation Criteria in Solid Tumours; rmSCCHN: recurrent/metastatic squamous cell carcinoma of the head and neck Inclusion Exclusion Aged ≥18 years Histologically/cytologically confirmed rmSCCHN HPV status known at randomisation Tumour CAFs level ≥5% First-line pembrolizumab candidate PD-L1 combined positive score ≥1 Measurable disease (RECIST 1.1) Tumour suitable for biopsy Active central nervous system metastases Prior pembrolizumab/setanaxib Active autoimmune disease in past 3 months/immunosuppression diagnosis Systemic steroid therapy ≤7 days prior to first dose
Clinical trial identification
NCT05323656.
Editorial acknowledgement
The authors acknowledge Krassimir Mitchev, MD, PhD, Calliditas Therapeutics AB, London, UK, for publication coordination and Tara Groves, BSc, Olivia Wakeman, BSc, and Sarah Jayne Clements, PhD, from Costello Medical, Cambridge, UK, for medical writing and editorial assistance based on the authors’ input and direction.
Legal entity responsible for the study
Calliditas Therapeutics Suisse SA.
Funding
Calliditas Therapeutics Suisse SA.
Disclosure
D.R. Adkins: Financial Interests, Advisory Role, Consulting: Merck, Cue Biopharma, Blue Print, Exelixis, Kura, Twoxar, Vaccinex, Xilio, Targimmune, Immunitas, Coherus, Eisai. P. Bossi: Financial Interests, Advisory Board, Advisory Board or Conference Honoraria: Merck, Sanofi-Regeneron, Merck Sharp & Dohme, Sun Pharma, Angelini, Molteni, Bristol Myers Squibb, GSK, Nestlé. E.E.W. Cohen: Financial Interests, Advisory Role, Consulting: Axelia, Cel Sci, Eisai, Hoopika, ImmunoSensor, Istari, Janssen, Kahr Medical, Mana Therapeutics, Merck, Mirati, MSD, Nectin Tx, Pangea Therapeutics, Roche; Financial Interests, Other, Data and Safety Monitoring Board: Ayala, Kura; Financial Interests, Member of the Board of Directors: National Comprehensive Cancer Network, Psioxus Therapeutics; Financial Interests, Stocks/Shares: Kinnate Biopharma, Primmune Therapeutics; Financial Interests, Advisory Board: Kinnate Biopharma. A. Daste: Financial Interests, Advisory Role, Consulting: Merck, Bristol Myers Squibb, MSD; Financial Interests, Advisory Board: Merck, Bristol Myers Squibb. K.J. Harrington: Financial Interests, Research Grant: AstraZeneca, Boehringer Ingelheim, MSD, Replimune; Financial Interests, Advisory Board: AstraZeneca, Arch Oncology, Bristol Myers Squibb, Boehringer Ingelheim, Codiak, Inzen, Merck Serono, MSD, Pfizer, Replimune. C. Le Tourneau: Financial Interests, Advisory Board: MSD, Bristol Myers Squibb, Merck Serono, Celgene, Roche, AstraZeneca, Nanobiotix, Seattle Genetics. L.F. Licitra: Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck Serono, MSD, Novartis, Pfizer, Roche, Buran; Financial Interests, Invited Speaker, Speaker Fees/Advisory Board: AstraZeneca, Bayer, MSD, Merck Serono, AccMed, Neutron Therapeutics, Inc. N. Little: Financial Interests, Personal, Advisory Role, Consulting: Calliditas Therapeutics AB. T. Morris: Financial Interests, Member of the Board of Directors: Oncotherics Ltd; Financial Interests, Advisory Role, Consulting: AstraZeneca Plc, Prism Ideas Ltd, Aptus Clinical Ltd, Medivir AB, Ascelia Pharma AB, Evgen Pharma Plc, Calliditas Therapeutics AB. M. Reinwald: Financial Interests, Advisory Board, Advisory Board/Honoraria: Roche, Bristol Myers Squibb, Boehringer-Ingelheim, AstraZeneca; Financial Interests, Research Grant: Gilead, Pfizer, Roche. All other authors have declared no conflicts of interest.
1370P - Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
- Andrew J. Armstrong (Durham, United States of America)
Abstract
Background
In PROpel (NCT03732820), pts were enrolled irrespective of HRR gene mutation (HRRm) status. However, determination of HRRm and evaluation of radiographic progression-free survival by HRRm status were predefined endpoints. TT testing is considered the reference for assessment of HRRm but, given potential challenges in obtaining sufficient quantity of quality TT, ctDNA testing was also conducted.
Methods
Archival TT and blood samples were collected at baseline from >98% of randomised pts and analysed by the FoundationOne®CDx and FoundationOneLiquid®CDx molecular diagnostic tests, respectively. HRRm status (HRRm, non-HRRm or HRRm unknown) was assigned by individual test result and using an aggregate of the results from both tests. For aggregate results, pts were classified as HRRm if an HRRm was detected by either test; non-HRRm if no HRRm was detected by either test; or HRRm unknown if they did not have a valid HRRm test result.
Results
Of the 796 pts randomized, 782 had TT samples and 794 had blood samples available for testing. Of the pts with TT samples, 535 (68%) were successfully assessed for HRRm status by TT test, while 734 (92%) of pts with blood samples were successfully assessed by ctDNA test. Aggregate HRRm status was obtained for 778 (98%) pts (226 HRRm, 552 non-HRRm and 18 HRRm unknown). Using TT as a reference, positive-percent agreement was 80%, negative-percent agreement was 87%, overall-percent agreement was 85% and the positive and negative predictive values were 64% and 94%, respectively. In the HRRm by ctDNA subgroup 51 pts were non-HRRm by TT. The negative predictive value suggests that in the non-HRRm by ctDNA subgroup ∼174/186 (94%) pts would also be non-HRRm by TT test. Therefore, there were ∼12 potential false negative results by ctDNA test in the total non-HRRm aggregate population (2% of 552 pts).
Conclusions
There was good agreement between matched TT and ctDNA test results in PROpel. Using aggregate test results, it was possible to maximize the number of pts with known HRRm status while controlling the number of potential false negative results, thus facilitating robust analysis of HRRm status.
Clinical trial identification
NCT03732820.
Editorial acknowledgement
Medical writing support was provided by Laura Smart, MChem, at Mudskipper Business Ltd., funded by AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
A.J. Armstrong: Financial Interests, Personal, Advisory Role: Janssen; Novartis; Myovant Sciences; Bayer; Exelixis; Dendreon; Merck; GoodRx; AstraZeneca; FORMA Therapeutics; Astellas Scientific and Medical Affairs Inc.; Pfizer; Bristol Myers Squibb; Exelixis; Financial Interests, Institutional, Funding: Gilead Sciences (Inst); Roche/Genentech (Inst); Bristol Myers Squibb (Inst); AstraZeneca (Inst); FORMA Therapeutics (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Pfizer (Inst); Amgen (Inst); Novartis (Inst); Jansse; Financial Interests, Institutional, Royalties: Circulating tumor cell novel capture technology (Inst); Financial Interests, Personal, Other, Travel/accommodation: Astellas Scientific and Medical Affairs Inc. F. Saad: Financial Interests, Personal, Other, Honoraria: AbbVie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Financial Interests, Personal, Advisory Role: AbbVie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Financial Interests, Institutional, Funding: Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst). A. Thiery-Vuillemin: Financial Interests, Personal, Other, Honoraria: Pfizer; AstraZeneca; Sanofi; Janssen; Novartis; Ipsen; Roche/Genentech; Bristol Myers Squibb; MSD; Astellas Pharma; Financial Interests, Personal, Advisory Role: Pfizer; AstraZeneca; Sanofi; Janssen; Novartis; Ipsen; Roche; Bristol Myers Squibb; MSD; Astellas Pharma; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Personal, Other, Travel/accommodation: Roche; MSD; Janssen; Bristol Myers Squibb; AstraZeneca; Pfizer; Astellas Pharma; Ipsen. M. Oya: Financial Interests, Personal, Other, Honoraria: Bayer; Bristol Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Funding: Novartis; Pfizer. N.D. Shore: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bayer, BMS, Dendreon, Ferring, Janssen, Merck, MDxHealth, Pfizer, Sanofi, Tolmar. N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Invited Speaker: BMS, Janssen, BMS; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Leadership Role, Head of the Prostate Cancer Working group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Principal Investigator, Co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Leadership Role: Castration-resistant Prostate Cancer Registry. M. Ozguroglu: Financial Interests, Personal, Funding: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Institutional, Funding: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Personal, Other, Travel/Accommodation: BMS, Janssen, AstraZeneca. C. Gedye: Financial Interests, Institutional, Speaker’s Bureau: BMS, MSD, AZ, Iosen, Pfizer, AbbVie, Astellas, Amge; Financial Interests, Personal, Other, Travel support: BMS, MSD, Astellas; Financial Interests, Institutional, Other: MSD, BMS, Amgen. O. Sartor: Financial Interests, Personal, Advisory Role: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janss; Financial Interests, Personal, Funding: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio. C.H. Poehlein: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. P. Qiu: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. Y. Liu, L. Riva, L. Harrington, L. Barker, P.M.D. Del Rosario, A. Barnicle: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. N. Clarke: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Janssen; Bayer; AstraZeneca.
178P - Awareness of modifiable lifestyle risk factors and acceptability of secondary risk reduction services amongst Irish breast cancer survivors and oncology clinicians
- Clara Steele (Cork, Ireland)
Abstract
Background
Many patients (>75%) diagnosed with breast cancer in Ireland today will be cured and are at risk of dying from other cancers and non-communicable diseases. Breast cancer diagnosis provides a pivotal time point for education on modifiable risk factors and engagement with secondary risk reduction services. Our study set out to establish the level of awareness and acceptability of these areas, respectively.
Methods
A survey was developed for breast cancer survivors and oncology clinicians using previously validated questionnaires; the ‘Mitchelstown Cohort Survey’ and the ‘International Physical Activity Questionnaire’. IBM SPSS software (Version 28.0) was used for data analysis.
Results
Between September and December 2021, 322 patients and 29 clinicians attending the South Infirmary Victoria and Cork University Hospitals, completed the survey. Over 80% of patients and clinicians were aware of modifiable cancer risk factors. Only 1 in 5 clincians had training in secondary risk reduction however 90% of clinicians were willing to refer to services. Education had an impact on the likelihood of patient engagement (Table). Patients who smoked, had increased alcohol intake, or gained weight since diagnosis were more likely to engage with services ( Education level and likelihood to engage with secondary risk reduction services
Patients likely to engage (n/total) Primary Secondary Tertiary Pearson Chi-Square Weight gain prevention 165/318 13 42 110 Dietary education 182/318 13 50 119 Exercise education 199/318 13 52 134
Conclusions
This study identified that over 4 in 5 breast cancer survivors and oncology clinicians were aware of the importance of modifiable lifestyle risk factors. While 9 in 10 clinicians were willing to refer to secondary prevention services if available, the likelihood of patient engagement was associated with their ‘at risk’ behaviours and education level. Our study highlights the challenges of implementing health promotion programs in this cohort.
Legal entity responsible for the study
University College Cork.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.